Novavax Secures $60 Million in Government Funds
Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.
Novavax announced a $60 million contract with the US Department of Defense to support the production of several components of NVXâCoV2373, its COVID-19 vaccine candidate. The agreement includes delivery in 2020 of 10 million doses of NVXâCoV2373 that can be used in Phase 2/3 clinical trials or under an Emergency Use Authorization if approved by FDA.
In a June 4, 2020 press statement, Novavax reported that the company will work with US-based contract development manufacturing organizations (CDMOs) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine and will collaborate with US-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.
Previously, Novavax announced that it has secured two manufacturing agreements for the large-scale manufacture of components of the vaccine candidate.
Source: Novavax
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Meeting Secondary Packaging Challenges of Innovative Delivery Systems for Biologics
February 6th 2025Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.
